Feedback
Settings

Settings

Goto Application

1. WO2018099988 - NK-MEDIATED IMMUNOTHERAPY AND USES THEREOF

PermaLink
Publication Number WO/2018/099988
Publication Date 07.06.2018
International Application No. PCT/EP2017/080848
International Filing Date 29.11.2017
IPC
C12N 5/0783 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 2501/2302
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
20Cytokines; Chemokines
23Interleukins [IL]
2302Interleukin-2 (IL-2)
C12N 2501/2312
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
20Cytokines; Chemokines
23Interleukins [IL]
2312Interleukin-12 (IL-12)
C12N 2501/2315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
20Cytokines; Chemokines
23Interleukins [IL]
2315Interleukin-15 (IL-15)
Applicants
  • FONDAZIONE RI.MED [IT]/[IT]
  • ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE . ISMETT [IT]/[IT]
Inventors
  • BADAMI, Ester
Agents
  • CAPASSO, Olga
  • TRILLAT, Anne-Cécile
  • TURRI, Elisa
Priority Data
10201600012108129.11.2016IT
Publication Language English (en)
Filing Language English (en)
Designated States
Title
(EN) NK-MEDIATED IMMUNOTHERAPY AND USES THEREOF
(FR) IMMUNOTHÉRAPIE MÉDIÉE PAR NK ET SES UTILISATIONS
Abstract
(EN) The present invention refers to a method for the production of activated CD3-CD56+ NK cells, activated CD3-CD56 NK+ cells obtainable with said method, their use, in particular for the treatment of a tumor, preferably a hepatocellular carcinoma (HCC), for use in the treatment and/or prevention of an HCV infection, for use in the treatment and/or prevention of a post-liver transplant HCV reinfection, or for use for prevention of a post-liver transplant HCC recurrence. The invention also concerns pharmaceutical compositions including said activated CD3 -CD56+ NK cells.
(FR) La présente invention concerne un procédé de production de cellules NK CD3-CD56+ activées, les cellules NK CD3-CD56+ activées pouvant être obtenues par ledit procédé, leur utilisation, en particulier pour le traitement d'une tumeur, de préférence un carcinome hépatocellulaire (HCC), destinées à être utilisées dans le traitement et/ou la prévention d'une infection par le VHC, destinées à être utilisées dans le traitement et/ou la prévention d'une réinfection par le VHC après transplantation du foie, ou destinées à être utilisées dans la prévention d'une récurrence de HCC après transplantation du foie. L'invention concerne également des compositions pharmaceutiques comprenant lesdites cellules NK CD3 -CD56+ activées.
Related patent documents
IT201600121081
EP3548610
US20190322985
DK3548610

Latest bibliographic data on file with the International Bureau

The publication of an international application under the Patent Cooperation Treaty in PATENTSCOPE (which constitutes an element of the Gazette) does not imply the expression of any opinion whatsoever on the part of the International Bureau of WIPO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

# -